PT929567E - Sintese em fase solida de peptidos - Google Patents

Sintese em fase solida de peptidos

Info

Publication number
PT929567E
PT929567E PT97939974T PT97939974T PT929567E PT 929567 E PT929567 E PT 929567E PT 97939974 T PT97939974 T PT 97939974T PT 97939974 T PT97939974 T PT 97939974T PT 929567 E PT929567 E PT 929567E
Authority
PT
Portugal
Prior art keywords
solid
phase
synthesis
peptid
relates
Prior art date
Application number
PT97939974T
Other languages
English (en)
Portuguese (pt)
Inventor
Arne Holm
Bjarne Due Larsen
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of PT929567E publication Critical patent/PT929567E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT97939974T 1996-09-09 1997-09-09 Sintese em fase solida de peptidos PT929567E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK97196 1996-09-09

Publications (1)

Publication Number Publication Date
PT929567E true PT929567E (pt) 2005-07-29

Family

ID=8099561

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97939974T PT929567E (pt) 1996-09-09 1997-09-09 Sintese em fase solida de peptidos

Country Status (14)

Country Link
US (1) US7348404B2 (enExample)
EP (1) EP0929567B1 (enExample)
JP (1) JP4405594B2 (enExample)
AT (1) ATE290014T1 (enExample)
AU (1) AU723268B2 (enExample)
CA (1) CA2265900C (enExample)
CZ (1) CZ295838B6 (enExample)
DE (1) DE69732640T2 (enExample)
DK (1) DK0929567T3 (enExample)
ES (1) ES2239364T3 (enExample)
HU (1) HU230354B1 (enExample)
IL (1) IL128829A (enExample)
PT (1) PT929567E (enExample)
WO (1) WO1998011125A1 (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7550425B2 (en) 2000-06-16 2009-06-23 Zealand Pharma A/S Diuretic peptide conjugates
WO2006045503A1 (en) 2004-10-19 2006-05-04 Lonza Ag Method for solid phase peptide synthesis
AU2006242998B2 (en) 2005-05-04 2012-03-22 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
GB0514071D0 (en) 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
JPWO2007060860A1 (ja) * 2005-11-22 2009-05-07 学校法人日本大学 ピロールイミダゾールポリアミドの固相自動合成
CN101336229B (zh) 2005-12-23 2012-06-13 西兰岛药物有限公司 改性的拟赖氨酸化合物
EP1991560B1 (en) * 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
CA2647867C (en) * 2006-03-29 2015-11-03 Otsuka Chemical Co., Ltd. Method for production of peptide thioester compound
EP2051995B1 (en) 2006-11-08 2017-02-08 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
JP5635530B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
DK2370461T3 (da) 2008-12-15 2013-12-16 Zealand Pharma As Glucagonanaloger
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
JP5969461B2 (ja) 2010-04-27 2016-08-17 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
WO2013098408A1 (en) 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
TW201336864A (zh) 2012-02-03 2013-09-16 Zealand Pharma As 胃飢餓素（ｇｈｒｅｌｉｎ）類似物
EP2844670B1 (en) 2012-05-03 2017-12-06 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN105051067B (zh) 2013-03-12 2020-04-17 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US9695214B2 (en) 2013-03-15 2017-07-04 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
DK2976325T3 (en) 2013-03-21 2017-06-06 Sanofi Aventis Deutschland SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
AU2014234400B2 (en) 2013-03-21 2017-11-16 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
CA2926314C (en) 2013-10-17 2023-08-29 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
KR102500408B1 (ko) 2014-01-27 2023-02-16 몰레큘러 템플레이츠, 인코퍼레이션. 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드
PL3604333T3 (pl) 2014-03-11 2021-11-08 Molecular Templates, Inc. Białka zawierające regiony efektorowe podjednostki a toksyny shiga proksymalnie do końca aminowego oraz celujące w komórki regiony wiążące typu immunoglobuliny zdolne do swoistego wiązania cd38
US20170002046A1 (en) 2014-03-11 2017-01-05 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
CN113831416A (zh) 2014-06-11 2021-12-24 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
WO2015200883A2 (en) 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
WO2016077840A2 (en) 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
ES2856457T3 (es) 2015-02-05 2021-09-27 Molecular Templates Inc Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas
JP6769984B2 (ja) 2015-03-18 2020-10-14 ジーランド ファーマ アクティーゼルスカブ アミリン類似体
GB201506380D0 (en) 2015-04-15 2015-05-27 Serodus Asa Materials and methods for treatment of pulmonary hypertension
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
CN107849096B (zh) 2015-05-30 2022-05-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
AU2016297920A1 (en) 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
CN108290923A (zh) 2015-09-17 2018-07-17 麻省理工学院 用于固相肽合成的方法和系统
US11097010B2 (en) 2016-08-06 2021-08-24 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
BR112019011859A2 (pt) 2016-12-09 2019-10-29 Zealand Pharma As agonista duplo de glp-1/glp-2, composição, método para aumentar massa intestinal, método de profilaxia ou tratamento de má-absorção intestinal e uso de um agonista duplo
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
RU2753193C2 (ru) 2016-12-09 2021-08-12 Зилэнд Фарма А/С Ацилированные двойные агонисты glp-1/glp-2
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
ES2894629T3 (es) 2017-06-16 2022-02-15 Zealand Pharma As Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
CA3080351A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
JP7690287B2 (ja) 2018-02-27 2025-06-10 セトペー エスペーベー ３ コマンディト セルスカブ コンプスタチン類似体及びその医療用途
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
US12258414B2 (en) 2018-06-22 2025-03-25 Ossianix, Inc. Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
US12351642B2 (en) 2018-09-14 2025-07-08 Ossianix, Inc. TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
EP3914358A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
CA3127660A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
EP3982920A1 (en) 2019-06-14 2022-04-20 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
CN114630836A (zh) 2019-08-27 2022-06-14 西兰制药第三特殊目的公司 补体抑制素类似物及其医学用途
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
TW202116350A (zh) 2019-09-20 2021-05-01 丹麥商西蘭製藥公司 Kv1.3阻斷劑
US20210155671A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
US20230129788A1 (en) 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CN116209671A (zh) 2020-07-16 2023-06-02 西兰制药第三特殊目的公司 补体因子c3的抑制剂及其医学用途
WO2022103769A1 (en) 2020-11-11 2022-05-19 Ossianix, Inc. High affinity human and monkey specific tfr-1 vnars
TW202241491A (zh) 2020-12-16 2022-11-01 丹麥商西蘭製藥公司 Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物
WO2022129311A1 (en) 2020-12-16 2022-06-23 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
US20240299552A1 (en) 2020-12-16 2024-09-12 Zealand Pharma A/S Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
US20240316155A1 (en) 2021-02-18 2024-09-26 Zealand Pharma A/S Composition for treating short bowel syndrome
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
AU2022245193A1 (en) 2021-03-23 2023-09-07 Zealand Pharma A/S Kv1.3 blockers
WO2022260877A1 (en) 2021-06-07 2022-12-15 Ossianix, Inc. Shark vnars for treating covid-19
US20240279298A1 (en) 2021-06-18 2024-08-22 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Glucagon analog and medical use thereof
US20250122298A1 (en) 2021-08-17 2025-04-17 Ossianix, Inc. Deimmunized vnar domains and scaffolds
JP2024533153A (ja) 2021-09-03 2024-09-12 ジーランド ファーマ エー／エス 投薬レジーム
EP4440592A1 (en) 2021-12-01 2024-10-09 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
EP4604984A1 (en) 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors
WO2024168411A1 (pt) * 2023-02-15 2024-08-22 Proteimax Bio Technology Israel Ltd Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism
WO2025120002A1 (en) 2023-12-04 2025-06-12 Zealand Pharma A/S Petrelintide for reducing weight whilst preserving lean mass
TW202530247A (zh) 2023-12-04 2025-08-01 丹麥商西蘭製藥公司 方法
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2025259861A2 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Antimicrobial peptides against citrus greening
WO2025259842A2 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Novel alpha-factor based peptides with antifungal activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116666A (enExample) * 1974-07-30 1976-02-10 Shionogi Seiyaku Kk
US5021550A (en) * 1986-10-07 1991-06-04 Thomas Jefferson University Method for preventing deletion sequences in solid phase synthesis
JP2807287B2 (ja) * 1989-10-13 1998-10-08 株式会社医学生物学研究所 ペプチドおよびその用途
EP0719334A1 (en) * 1993-09-14 1996-07-03 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US7176282B1 (en) * 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

Also Published As

Publication number Publication date
EP0929567A1 (en) 1999-07-21
CA2265900A1 (en) 1998-03-19
HU230354B1 (hu) 2016-02-29
IL128829A (en) 2005-08-31
CZ295838B6 (cs) 2005-11-16
HUP0102900A3 (en) 2002-02-28
CZ80399A3 (cs) 1999-08-11
ES2239364T3 (es) 2005-09-16
JP4405594B2 (ja) 2010-01-27
WO1998011125A1 (en) 1998-03-19
JP2001500134A (ja) 2001-01-09
AU723268B2 (en) 2000-08-24
US20070004905A1 (en) 2007-01-04
DK0929567T3 (da) 2005-06-27
US7348404B2 (en) 2008-03-25
HUP0102900A2 (hu) 2002-01-28
CA2265900C (en) 2007-07-31
AU4199397A (en) 1998-04-02
IL128829A0 (en) 2000-01-31
DE69732640T2 (de) 2006-01-12
DE69732640D1 (de) 2005-04-07
EP0929567B1 (en) 2005-03-02
ATE290014T1 (de) 2005-03-15

Similar Documents

Publication Publication Date Title
PT929567E (pt) Sintese em fase solida de peptidos
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
ES2193363T3 (es) Peptidos ciclicos que se unen al receptor del activador de plasminogeno de tipo uroquinasa.
TR200001985T2 (tr) Kapa reseptörü opioid peptidleri.
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
DK0695757T3 (da) Peptidamider til inhibering af human cancer
EP1115739A4 (en) AUXILIARY AID FOR FORMING AMID BOND
ATE394482T1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
SE9903291D0 (sv) New process
FI961044A7 (fi) Kininogeeni-inhibiittorit
AU580350B2 (en) Process for synthesising peptides
FI953525L (fi) Kemiallinen syntetointimenetelmä fibronektiiniä sitovan proteiinin tai polypeptidin valmistamiseksi
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
HUT55800A (en) Process for producing anticoagulant peptides
WO1997044354A3 (en) Synthesis of soluble beta-sheet forming peptides
DE69227517D1 (de) Produktion von peptid-amiden
DK0853484T3 (da) Hidtil ukendte MU-opioid-receptorligander: agonister og antagonister
GR3021660T3 (en) Anticoagulant peptides
MY128151A (en) Substance p analogs for the treatment of cancer
IT1264598B1 (it) Intermedi per la preparazione di peptidi retro-inversi
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins
IT9019697A0 (it) Nuovo derivato del 9h-xantene utile per la sintesi in fase solida di peptidi in forma di ammidi c-terminali